Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : 2026 TeoTwawKi ... 2032 Darkest Interregnum -- Ignore unavailable to you. Want to Upgrade?

To: arun gera who wrote (165059)	11/11/2020 9:14:27 PM
From: sense	Read Replies (1) \| Respond to of 217808

A pretty simple matter... that I got right at the time, and not re-inventing it now ? The math works. Once you peg the right equations... its quite predictive. And, the metric in the occupancy, as you noted... is kind of hard to argue with... If the hospitals are empty... that's a tell. If they're overly full... same thing. Otherwise, is a matter of percentages versus TIME... and not overly complex rate computations... Either go MORE draconian... to kill it off entirely in less time... by isolation rather than quarantine... or massage the numbers realizing you can't make everything stop without hurting people more from stopping everything than from having them get the virus. But short of isolation... quarantine that slows it dramatically, but temporarily, only prolongs it... making it more disruptive ? Isolation unlikely to work beyond early stage timely action. Delay... if you do have ability to improve treatment fast... makes sense. That's we we are now ? Mortality is way down ? That's not because "it was always not a real threat" as some pose now. My guess is a lot will be learned from this bug... about re-prioritizing work and resources to find better treatment options faster, rather that focus on vaccines... Genomics focused on treatment probably more useful than doing what Pasteur and Bill Gates would want to do ? The responses of the medical community with primary responsibility for this... were abysmal... just could not have been worse... A real challenge, now, trying to restore trust... that was not well placed before.

To: arun gera who wrote (165059)	11/11/2020 10:22:31 PM
From: TobagoJack	Respond to of 217808

in the meantime Team Brazil does what it deems truly necessary and cut the political cr@pola, just in case direly wrong let us see if Bolsonaro also suffers a suspect 49/51 electioneering bloomberg.com China’s CoronaVac Trial Resumes in Brazil After ‘Adverse Event’ Simone Preissler Iglesias Brazil reversed its decision to suspend trials of a coronavirus vaccine from Chinese developer Sinovac Biotech Ltd., allowing tests to resume less than 48 hours after being halted amid criticism the initial pause was politically motivated. In a statement posted on its website Wednesday, health agency Anvisa said it initially got “precarious data” on a “grave” event, which led it to suspend the study late Monday. The agency added that it reversed its previous ruling after receiving new information, and that it will keep monitoring the case. Read More: Brazil’s Halting of China Vaccine Baffles Local Researchers On Tuesday, Sao Paulo’s Instituto Butantan, which partnered with Sinovac to produce the vaccine locally, criticized the suspension, saying it was not warned of the move and that the reported death of a volunteer was not related to the shot. Sinovac’s vaccine has become the focus of an escalating feud in Brazil. President Jair Bolsonaro stepped up criticism of CoronaVac last month, sayingChina lacks credibility to come up with solutions for the coronavirus crisis and that people wouldn’t feel safe with the shot “due to its origin.” Chinese vaccine developers have been compelled to find countries where the coronavirus is still spreading to host their final-stage trials, since the Asian nation’s domestic outbreak has been largely contained. Geopolitical tensions have affected the development process due to growing hostility toward Beijing from some countries over a range of issues like trade and the pandemic’s origins. After the trial was paused, Bolsonaro on his Facebook account responded to a supporter and appeared to celebrate the decision, writing, “another win for Bolsonaro.” He has not commented on the resumption of the trial. The Butantan researchers have suggested the participant could have died in a traffic accident, while Anvisa said earlier it had no information about the potential cause of death being suicide as reported by local media. China’s Race for Covid-19 Vaccine Raises Safety Questions “The decision to interrupt without having all the details seems premature,” said Juarez Cunha, head of the Brazilian Immunization Society. “Given Butantan’s credibility, I am sure if there was any suspicion of a related grave adverse event, the researchers themselves would have called attention to it and suggested the suspension.” Sinovac said in a statement on its website earlier this week that it’s confident in the safety of its vaccine. Halts to investigate serious adverse events are not uncommon in large-scale drug trials and two western developers -- AstraZeneca Plc and Johnson & Johnson -- paused their vaccine trials in recent months due to such incidents, only to re-start them after investigation. Chinese vaccine developers have been at the forefront of the global race to create an effective immunization against the virus. The push has taken on vital importance as countries look to move beyond Covid-19 and more definitively re-open their economies. Unlike American pharmaceutical firm Pfizer Inc., which this week revealed “ extraordinary” positive preliminary data from final-stage trials of its candidate developed with BioNTech, no Chinese developer has yet publicized data on the efficacy of their shots. — With assistance by Andre Romani Pinto Before it's here, it's on the Bloomberg Terminal. LEARN MORE